Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

Por Yu, H. A., Arcila, M. E., Hellmann, M. D., Kris, M. G., Ladanyi, M., Riely, G. J.
Publicado em 2014

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumo...

Por Kris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M. E., Goldberg, Z., Jänne, P. A.
Publicado no Ann Oncol (2015)

Clinical Characteristics and Course of 63 patients with BRAF Mutant Lung Cancers

Por Litvak, A.M., Paik, P.K., Woo, K. M., Sima, C. S., Hellmann, M. D., Arcila, M.E., Ladanyi, M., Rudin, C. M., Kris, M. G., Riely, G. J.
Publicado no J Thorac Oncol (2014)